Welcome to our dedicated page for Proassurance Cp SEC filings (Ticker: PRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for ProAssurance Corporation (NYSE: PRA), a specialty property and casualty insurance holding company focused on medical professional liability, products liability for medical technology and life sciences, and workers’ compensation insurance. These regulatory documents offer detailed information on ProAssurance’s financial condition, segment performance, governance, and its pending merger with The Doctors Company.
ProAssurance’s periodic reports, such as its Form 10-K and Form 10-Q filings (referenced in the company’s earnings releases and 8-Ks), include consolidated financial statements, segment disclosures for Specialty Property and Casualty, Workers’ Compensation Insurance, Segregated Portfolio Cell Reinsurance, Lloyd’s Syndicate, and Corporate, as well as discussions of key ratios, Non-GAAP measures, and risk factors. Investors use these filings to analyze underwriting results, reserve development, investment income, and capital metrics like book value per share and Non-GAAP adjusted book value per share.
The company’s Form 8-K filings highlight specific material events. In 2025, ProAssurance filed multiple 8-Ks to furnish quarterly earnings releases under Item 2.02, report the June 24, 2025 stockholder vote approving the merger agreement with The Doctors Company under Item 5.07, and describe progress on regulatory milestones such as early termination of the Hart-Scott-Rodino waiting period under Item 8.01. Another 8-K filed in December 2025 under Item 5.02 outlines compensatory arrangements for named executive officers in connection with the merger and explains how these payments relate to Section 280G of the Internal Revenue Code.
On Stock Titan, ProAssurance filings are updated as they are released on EDGAR. AI-powered summaries help explain the contents of lengthy documents, highlight key changes from prior periods, and surface important items such as segment results, merger-related disclosures, and executive compensation arrangements. Users can review Forms 10-K and 10-Q for comprehensive financial information, 8-Ks for transaction and earnings announcements, and other filings that document ProAssurance’s regulatory history and its planned transition to a wholly owned subsidiary of The Doctors Company.
ProAssurance (PRA) Q2-25 10-Q highlights: Net premiums earned slipped 3% YoY to $232.4 m, but higher investment income (+6% to $38.9 m) and a 14% drop in loss costs lifted quarterly net income 41% to $21.9 m (diluted EPS $0.42). Six-month revenues fell 5% to $548.8 m and net income declined 20% to $16.1 m (EPS $0.31) after $11.6 m merger-related expenses.
Shareholders’ equity rose 6% since year-end to $1.28 bn as AOCI improved $55.8 m with bond-market recovery. Book value approximates $24–25 per share, near the $25 cash offer in the pending merger with The Doctors Company. The deal, signed 19 Mar 25, gained shareholder approval 24 Jun 25 and early HSR clearance 2 Jul 25; closing targeted 1H-26, pending remaining regulatory consents.
- Combined ratio (est.) improved to ~96.4% from ~98.2%.
- Operating cash flow YTD: –$39.7 m (–$24.5 m PY).
- Investment portfolio $4.38 bn; unrealized loss narrowed to $116.6 m.
- Debt $422.6 m; net leverage ~0.3× equity.
- Sale of Franklin, TN property generated $19.3 m cash and $2.2 m gain.
No new accounting standards adopted; upcoming FASB disclosure rules being evaluated.
Date: August 5, 2025. Event: ProAssurance Corporation (PRA) furnished a news release reporting results of operations for the quarter ended June 30, 2025 as Exhibit 99.1 to this Form 8-K.
Disclosure: The company also updated online disclosure of its entire investment portfolio with holdings through June 30, 2025, available under Quarterly Results in the Financial Information section of its Investor Relations website. The filing states the furnished information is not being "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated. The Form 8-K is signed by Jeffrey P. Lisenby, General Counsel.
ProAssurance Corporation (NYSE: PRA) reported that shareholders overwhelmingly approved all proposals connected with its pending merger with The Doctors Company at a special meeting held on 24 June 2025.
• Merger Agreement adoption: 38,225,337 shares voted FOR, just 363,050 AGAINST and 22,192 ABSTAIN; no broker non-votes were recorded. Support exceeded 99% of votes cast, comfortably surpassing any approval threshold.
• Say-on-Pay (merger-related compensation): 31,191,544 FOR, 7,185,578 AGAINST, 233,457 ABSTAIN—an 81% approval rate on an advisory basis.
• Adjournment proposal: Not required because quorum (≈75.6% of outstanding 51,070,243 shares) was achieved and the merger proposal passed.
Under the Agreement and Plan of Merger signed 19 March 2025, Jackson Acquisition Corporation (a wholly owned subsidiary of The Doctors Company) will merge with and into ProAssurance, making ProAssurance a wholly owned subsidiary of The Doctors Company. Management currently expects closing in the first half of 2026, subject to regulatory clearances and other customary conditions.
The filing reiterates extensive forward-looking risk factors, including regulatory approvals, potential litigation, business disruption, personnel retention and market reactions during the pre-closing period. A related news release (Exhibit 99.1) announcing the vote results was issued the same day.